These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8538479)

  • 1. Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome.
    Gambacciani M; Spinetti A; Orlandi R; Piaggesi L; Cappagli B; Weiss C; Ciaponi M; Genazzani AR
    Maturitas; 1995 Sep; 22(2):115-20. PubMed ID: 8538479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate).
    Alwers R; Urdinola J; Onatra W; Sánchez F; Posso H
    Maturitas; 1999 May; 32(1):41-50. PubMed ID: 10423715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effect of two hormonal preparations in postmenopausal women.
    Bissonnette F; Lussier-Cacan S; Fugère P; Bérubé S
    Maturitas; 1997 Jul; 27(3):275-84. PubMed ID: 9288700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized cross-over study of a 21-day versus a 28-day hormone replacement therapy (HRT).
    McCarthy T; Dramusic V; Carter R; Costales A; Ratnam SS
    Maturitas; 1995 Jun; 22(1):13-23. PubMed ID: 7666812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
    Schram JH; Boerrigter PJ; The TY
    Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does vitamin D3 have negative effects on serum levels of lipids? A follow-up study with a sequential combination of estradiol valerate and cyproterone acetate and/or vitamin D3.
    Tuppurainen M; Heikkinen AM; Penttilä I; Saarikoski S
    Maturitas; 1995 Jun; 22(1):55-61. PubMed ID: 7666817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term sequential treatment with combined estradiol valerate and cyproterone acetate in early postmenopause.
    Polatti F; Capuzzo E; Viazzo F; Colleoni R; Abbiati I; Nappi RE
    Acta Obstet Gynecol Scand; 1999 Jan; 78(1):49-53. PubMed ID: 9926892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    Heikkinen J; Kyllönen E; Kurttila-Matero E; Wilén-Rosenqvist G; Lankinen KS; Rita H; Väänänen HK
    Maturitas; 1997 Mar; 26(2):139-49. PubMed ID: 9089564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine effects in Asian postmenopausal women treated with SH D 461 M and Prempak-C.
    Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
    Maturitas; 1994 Dec; 20(2-3):165-73. PubMed ID: 7715469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women.
    Georgiev DB; Golbs S; Goudev A
    Methods Find Exp Clin Pharmacol; 2001 May; 23(4):197-202. PubMed ID: 11676228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
    Marslew U; Overgaard K; Riis BJ; Christiansen C
    Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen versus oestrogen monotherapy.
    Metka M; Hanes V; Heytmanek G
    Maturitas; 1992 Aug; 15(1):53-9. PubMed ID: 1326708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and risks of different hormonal replacement therapies in post-menopausal women.
    Volpe A; Facchinetti F; Grasso A; Petraglia F; Campanini D; Genazzani AR
    Maturitas; 1986 Dec; 8(4):327-34. PubMed ID: 3033444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation.
    Koninckx PR; Lauweryns JM; Cornillie FJ
    Maturitas; 1993 Mar; 16(2):97-110. PubMed ID: 8387151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women.
    Jensen J; Riis BJ; Strøm V; Christiansen C
    Maturitas; 1989 Jun; 11(2):117-28. PubMed ID: 2547137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of a sequential combination of estradiol valerate and cyproterone acetate on the functional properties of the arterial wall in menopausal women].
    Mares P; Dauzat M; Abramovici Y; Deklunder G; Body G; Crepin G; Denis A; Favier M
    Gynecol Obstet Fertil; 2000; 28(7-8):509-17. PubMed ID: 10996962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estradiol valerate/cyproterone acetate in the treatment of climacteric syndrome].
    Zivný J; Skrenková J
    Ceska Gynekol; 1996 Oct; 61(5):294-6. PubMed ID: 9004975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease.
    Vitale C; Fini M; Leonardo F; Rossini P; Cerquetani E; Onorati D; Rosano GM
    Maturitas; 2001 Dec; 40(3):239-45. PubMed ID: 11731185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins.
    Jensen J; Riis BJ; Christiansen C
    Br J Obstet Gynaecol; 1987 Feb; 94(2):136-41. PubMed ID: 3030392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.